About
Latigo Biotherapeutics, Inc.
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction.
The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain.
Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019.
Latigo Biotherapeutics, Inc. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Change from offer price to today
Live Market Snapshot
Real-time price; headline % change is vs first trade (listing price)
USD · NASDAQ:NASDAQ:LTGO
Valuation & Multiples
Key valuation ratios and metrics
Financial Health
Balance sheet strength and liquidity
Risk Metrics
Volatility versus the market
Financial Highlights
Historical financial performance
Historical Data
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-08-27 | $24.15 | $25.93 | $24.08 | $25.00 | $25.00 | +0.85 | 235,500 |
| 2026-08-26 | $22.64 | $24.79 | $22.37 | $24.13 | $24.13 | +1.49 | 137,900 |
| 2026-08-25 | $22.07 | $22.76 | $21.74 | $22.57 | $22.57 | +0.50 | 142,800 |
| 2026-08-24 | $22.62 | $25.00 | $21.42 | $22.00 | $22.00 | -0.62 | 234,100 |
| 2026-08-21 | $21.52 | $22.90 | $20.64 | $22.37 | $22.37 | +0.85 | 197,200 |
| 2026-08-20 | $20.75 | $21.71 | $20.52 | $21.40 | $21.40 | +0.65 | 82,700 |
| 2026-08-19 | $20.00 | $21.11 | $20.00 | $20.94 | $20.94 | +0.94 | 175,600 |
| 2026-08-18 | $19.17 | $20.05 | $19.00 | $20.00 | $20.00 | +0.83 | 255,000 |
| 2026-08-17 | $19.49 | $19.62 | $19.00 | $19.30 | $19.30 | -0.19 | 172,200 |
| 2026-08-14 | $20.01 | $20.10 | $18.46 | $19.49 | $19.49 | -0.52 | 303,600 |
| 2026-08-13 | $19.46 | $20.49 | $19.25 | $20.06 | $20.06 | +0.60 | 273,500 |
| 2026-08-12 | $18.52 | $19.62 | $18.50 | $19.38 | $19.38 | +0.86 | 208,200 |
| 2026-08-11 | $18.41 | $18.97 | $18.20 | $18.52 | $18.52 | +0.11 | 237,900 |
| 2026-08-10 | $18.10 | $19.00 | $17.22 | $18.56 | $18.56 | +0.46 | 598,400 |
| 2026-08-07 | $21.00 | $22.47 | $18.19 | $18.25 | $18.25 | -2.75 | 3,301,700 |
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| SCHEDULE 13G | Aug 18, 2026 | Filing |
| SCHEDULE 13D | Aug 17, 2026 | Filing |
| SCHEDULE 13G | Aug 17, 2026 | Filing |
| SCHEDULE 13G | Aug 13, 2026 | Filing |
| S-8 | Aug 10, 2026 | Securities to be offered to employees in employee benefit plans |
| 8-K | Aug 10, 2026 | Current Report |
| 424B4 | Aug 7, 2026 | Prospectus |
| EFFECT | Aug 6, 2026 | Notice of Effectiveness |
| S-1MEF | Aug 6, 2026 | Registration adding securities to prior Form S-1 registration |
| CERT | Aug 6, 2026 | Certification by an exchange approving securities for listing |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Nima Farzan
Director, President and Chief Executive Officer
Neha Krishnamohan
Chief Financial Officer and Chief Business Officer
Neil Singla, M.D.
Chief Medical Officer
Timothy P. Walbert
Chair
Sara Bonstein
Director
Deborah Palestrant, Ph.D.
Director
Kevin Raidy
Director
Beth Seidenberg, M.D.
Director
Todd N. Smith
Director
James B. Tananbaum, M.D.
Director
